The global asthma treatment market size is expected to reach around US$ 25.8 billion by 2030 from US$ 30.1 billion in 2021 and is expected to grow at an impressive double-digit rate of 2.6% from 2022 to 2030. The rising prevalence of asthma due to increasing levels of pollution is expected to augment the growth of the market.
The study includes drivers and restraints of this market. The study provides an analysis of the global asthma treatment market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
There has been a strong relation established between psychological disorders and its impact on asthma. The increasing occurrence of psychological disorders is expected to trigger asthma in patients, especially for those whose ailment in severely undertreated. This is expected to drive the global market growth. However, studies have found that there is a severe lack of adherence to asthma treatment, especially, in underdeveloped countries and an array of unmet needs. These factors are expected to hamper the market growth. Nonetheless, biologics for asthma management are expected to open new growth opportunities.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1557
Why should you invest in this report?
If you are aiming to enter the global asthma treatment market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for asthma treatment are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global asthma treatment market include:
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Roche Holding AG / Novartis AG
- Merck & Co., Inc.
- Koninklijke Philips N.V.
- Sanofi-Aventis SA
- MundiPharma.
Market Segmentation
By Medication
- Quick-relief medication
- Long-term control medication
By Route of Administration
- Inhalers
- Prefilled syringes/vials
- Others
By Adjunct Therapy
- LAMA (long-acting muscarinic antagonists)
- LABA (long-acting beta antagonists)
- Others
By Distribution Channel
- Online pharmacies
- Hospital pharmacies
- Retail pharmacies & drug stores
Regional Analysis:
The geographical analysis of the global asthma treatment market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global asthma treatment Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global asthma treatment market in 2030?
- What is the expected CAGR for the asthma treatment market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global asthma treatment market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Asthma Treatment Market
5.1. COVID-19 Landscape: Asthma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Asthma Treatment Market, By Medication
8.1. Asthma Treatment Market, by Medication Type, 2021-2027
8.1.1. Quick-relief medication
8.1.1.1. Market Revenue and Forecast (2019-2027)
8.1.2. Long-term control medication
8.1.2.1. Market Revenue and Forecast (2019-2027)
Chapter 9. Global Asthma Treatment Market, By Route of Administration
9.1. Asthma Treatment Market, by Route of Administration, 2021-2027
9.1.1. Inhalers
9.1.1.1. Market Revenue and Forecast (2019-2027)
9.1.2. Prefilled syringes/vials
9.1.2.1. Market Revenue and Forecast (2019-2027)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 10. Global Asthma Treatment Market, By Adjunct Therapy
10.1. Asthma Treatment Market, by Adjunct Therapy, 2021-2027
10.1.1. LAMA (long-acting muscarinic antagonists)
10.1.1.1. Market Revenue and Forecast (2019-2027)
10.1.2. LABA (long-acting beta antagonists)
10.1.2.1. Market Revenue and Forecast (2019-2027)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 11. Global Asthma Treatment Market, By Distribution Channel
11.1. Asthma Treatment Market, by Distribution Channel, 2021-2027
11.1.1. Online pharmacies
11.1.1.1. Market Revenue and Forecast (2019-2027)
11.1.2. Hospital pharmacies
11.1.2.1. Market Revenue and Forecast (2019-2027)
11.1.3. Retail pharmacies & drug stores
11.1.3.1. Market Revenue and Forecast (2019-2027)
Chapter 12. Global Asthma Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.1.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.1.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.2.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.2.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.3.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.3.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.7.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.7.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Medication (2019-2027)
12.4.8.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.4.8.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.5.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.5.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Medication (2019-2027)
12.5.6.2. Market Revenue and Forecast, by Route of Administration (2019-2027)
12.5.6.3. Market Revenue and Forecast, by Adjunct Therapy (2019-2027)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2027)
Chapter 13. Company Profiles
13.1. AstraZeneca
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Boehringer Ingelheim International GmbH
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Roche Holding AG / Novartis AG
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi-Aventis SA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. MundiPharma
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1557
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments